Objective: Arterial Stiffness (AS) and Non-Alcoholic Fatty Liver Diseases (NAFLD) are 2
related, prevalent, risk predictors of Cardiovascular Disease (CVD). We assessed the effect of low dose
(5 mg/day) vs. high dose (20-40 mg/day) rosuvastatin on aortic elasticity and central haemodynamics as
well as on NAFLD in patients with Arterial Hypertension (AH).
Methods: Forty patients with optimally controlled AH were randomised to 2 rosuvastatin doses and
followed for 6 months. 24h AS was assessed by Mobil-O-Graph, which calculates (adjusted for age and
gender) Pulse Wave Velocity (PWV), adjusted for Heart Rate (HR) augmentation index (AIx75%) and
central haemodynamics. The diagnosis of NAFLD was based on >5% liver steatosis on ultrasound and
moderately elevated serum levels of liver enzymes.
Results: Both doses of rosuvastatin reduced Central Pulse Pressure (cPP), PWV and AIx75% (adjusted
for HR) to normal values (p = NS adjusted for age, gender and HR). Liver enzymes were reduced in
those with NAFLD to normal, but steatosis was reduced more by the 20-40 mg/day rosuvastatin dose
(p=0.01) compared with the 5 mg/day dose.
Conclusion: Both doses of rosuvastatin had a beneficial effect on AS; the high dose was more efficient
in reducing PWVs and central haemodynamics, and also the high dose was more effective in ameliorating
NAFLD. Given that AH control was optimal and lipid values attained targets, 4 other CVD predictors
were also addressed. Larger and longer term studies are needed to demonstrate the clinical benefit
of such treatment preference.